Hickey Benjamin
SEC-identified person · CIK 1753055 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Bristol Myers Squibb CO BMY | President, RayzeBio Org. | filed 2024 - 2026 |
| Mural Oncology plc MURA US | Director | filed 2023 - 2025 |
| Mirati Therapeutics, Inc. mrtx | EVP, Chief Commercial Officer | filed 2020 - 2024 |
| Surface Oncology, Inc. SURF | Director | filed 2021 - 2022 |
| Halozyme Therapeutics, INC. Halo | SVP, Chief Commerical Officer | filed 2018 - 2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.